Novo Nordisk said on Wednesday it plans to launch its weight-loss pill Wegovy in vials.
“We are exploring various device presentations for Wegovy, including vials – some are launching this year, others are coming in the future,” the company said.
Novo currently sells Wegovy in injectable and oral versions.
Rival Eli Lilly started selling vials of the two lowest doses of its popular weight-loss drug Zepbound in 2024.
Last year, Lilly cut the price for vials of Zepbound by $50 or more and expanded the range of doses sold online.
Novo and Lilly are locked in a tightening fight in the obesity-drug market, with Novo trying to win back its crown after a bruising year in which Zepbound overtook Wegovy in U.S. prescriptions.
Novo Nordisk Plans to Launch Wegovy Vials
Popular Categories
Previous article![]( "Rebalancing Skin Care Products Market Gains Momentum Across APAC, Europe, USA, and Saudi Arabia Driven by Personal Care")
Next article![]( "Lilly’s bowel disease drug gets approval in China")
